Panaji Journal

60+ Active Companies working to develop 60+ Pipeline Therapies for STAT Inhibitors Treatment Landscape Analysis

 Breaking News
  • No posts were found

60+ Active Companies working to develop 60+ Pipeline Therapies for STAT Inhibitors Treatment Landscape Analysis

April 06
14:09 2023
60+ Active Companies working to develop 60+ Pipeline Therapies for STAT Inhibitors Treatment Landscape Analysis

DelveInsight’s, “STAT Inhibitors Pipeline Insights 2023” report provides comprehensive insights about 60+ companies and 60+ pipeline drugs based on STAT Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For STAT Inhibitors Emerging Drugs, the STAT Inhibitors pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The STAT Inhibitors pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the STAT Inhibitors Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, STAT Inhibitors clinical trials studies, STAT Inhibitors NDA approvals (if any), and product development activities comprising the technology, STAT Inhibitors collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the STAT Inhibitors Pipeline Report

 

  • DelveInsight’s STAT Inhibitors Pipeline report depicts a robust space with 60+ active players working to develop 60+ pipeline therapies for STAT Inhibitors treatment.

 

  • The leading STAT Inhibitors Companies include Singh Biotechnology, AndroScience Corporation, Wyeth, Astellas, Dolthera, Jiangsu Hengrui Medicine, Otsuka Pharmaceutica, Daewoong Pharmaceutical, Novartis Pharmaceuticals, Pfizer, Shire, PPD, Takeda, CSL Behring, and others.

 

  • Promising STAT Inhibitors Pipeline Therapies include C1 Esterase Inhibitor, Lanadelumab, Icatibant, Tofacitinib, Lansoprazole, Aspirin, Dipyridamole, Aggrenox, Everolimus, and others.

 

  • The STAT Inhibitors Companies and academics that are working to assess challenges and seek opportunities that could influence STAT Inhibitors R&D. The STAT Inhibitors pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

  

For further information, refer to the detailed STAT Inhibitors Unmet Needs, STAT Inhibitors Latest Drugs Launch News, click here for STAT Inhibitors Ongoing Clinical Trial Analysis

 

STAT Inhibitors Emerging Drugs Profile

 

  • SHR0302: Jiangsu Hengrui Medicine

SHR0302 is a potent and orally active all members of the JAK family inhibitor, particularly JAK1. The selectivity of SHR0302 for JAK1 is >10-fold for JAK2, 77-fold for JAK3, 420-fold for Tyk2. It inhibits JAK1-STAT3 phosphorylation and induces the apoptosis of hepatic stellate cells. SHR0302 has an anti-proliferative and anti-inflammatory effect. It is currently in phase III stage of development.

 

  • OPB-111077: Otsuka Pharmaceutica

OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models.In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy.

 

  • Niclosamide intramuscular depot: Daewoong Pharmaceutical

Niclosamide intramuscular depot is being developed by Daewoong Pharmaceutical for the treatment of COVID 2019 infections. It is currently in phase I stage of development.

 

STAT Inhibitors Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies based on STAT Inhibitors. The companies which have their drug candidate based on STAT Inhibitors in the most advanced stage, i.e. phase II/III include Jiangsu Hengrui Medicine and others.

 

Request a sample and discover the recent advances in STAT Inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ STAT Inhibitors Treatment Landscape Analysis

 

Scope of the STAT Inhibitors Pipeline Report

 

  • Coverage- Global

 

  • STAT Inhibitors Companies- Singh Biotechnology, AndroScience Corporation, Wyeth, Astellas, Dolthera, Jiangsu Hengrui Medicine, Otsuka Pharmaceutica, Daewoong Pharmaceutical, Novartis Pharmaceuticals, Pfizer, Shire, PPD, Takeda, CSL Behring, and others.

 

  • STAT Inhibitors Pipeline Therapies- C1 Esterase Inhibitor, Lanadelumab, Icatibant, Tofacitinib, Lansoprazole, Aspirin, Dipyridamole, Aggrenox, Everolimus, and others.

 

  • STAT Inhibitors Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for STAT Inhibitors Market Drivers and STAT Inhibitors Market Barriers, click here @ STAT Inhibitors Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. STAT Inhibitors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. STAT Inhibitors – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. STAT Inhibitors Collaboration Deals
  9. Late Stage Products (Phase III)
  10. SHR0302: Jiangsu Hengrui Medicine
  11. Mid Stage Products (Phase II)
  12. OPB-111077: Otsuka Pharmaceutica
  13. Drug profiles in the detailed report…..
  14. Early Stage Products (Phase I)
  15. Niclosamide intramuscular depot: Daewoong Pharmaceutical
  16. Drug profiles in the detailed report…..
  17. Pre-clinical and Discovery Stage Products
  18. Drug Name: Company Name
  19. Inactive Products
  20. STAT Inhibitors Key Companies
  21. STAT Inhibitors Key Products
  22. STAT Inhibitors- Unmet Needs
  23. STAT Inhibitors- Market Drivers and Barriers
  24. STAT Inhibitors- Future Perspectives and Conclusion
  25. STAT Inhibitors Analyst Views
  26. STAT Inhibitors Key Companies
  27. Appendix

 

Got Queries? Find out the related information on STAT Inhibitors Mergers and acquisitions, STAT Inhibitors Licensing Activities @ STAT Inhibitors Emerging Drugs, and Recent Trends

 

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/